Market research
K3P.F Kiadis Pharma N.V
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 220M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 5.18
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 220M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 5.18
About
About Kiadis Pharma N.V
Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. It develops K-NK002 as an adjunctive immunotherapeutic for blood cancer patients undergoing a haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol; and K-NK003 for the treatment of patients with acute myeloid leukemia relapse/refractory. The company also develops K-NK-ID101 for the treatment of COVID-19 infection; and K-NK004 to treat multiple myeloma. In addition, it develops NK cell therapies for blood cancers and solid tumors. The company has a collaboration agreement with Sanofi. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. As of April 12, 2021, Kiadis Pharma N.V. operates as a subsidiary of Sanofi Foreign Participations B.V.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the K3P.F discussion.
5 years, 5 months ago
Kiadis Pharma N.V is currently in a long term uptrend where the price is trading 16.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Kiadis Pharma N.V gets an overall score of 2/5.